EnteroBiotix announces positive Phase 2 TrIuMPH results supporting EBX-102-02 as a potential first-in-class, oral, full-spectrum microbiome therapy for irritable bowel syndrome

Clinically meaningful improvements in global IBS symptom severity observed as early as Week 1 and sustained through Week 7, with EBX-102-02 ...
ascopubs.org

A single-blind, placebo-controlled, sequential design study evaluating the potential effects of trabectedin on the QT intervals.

Phase I study of ixabepilone in combination with capecitabine in Japanese patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Background: Trabectedin (Tr) is ...

Bayer’s BAY3018250 DVT Study Reaches Completion: What It Means for Investors

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.